Philip Budge and colleagues reveal a faster route to eliminating parasitic infection endemic to Africa

A small clinical trial in Cote d’Ivoire, led by researchers at Washington University School of Medicine in St. Louis, shows that the anti-parasitic drug moxidectin — currently approved to treat river blindness, another tropical disease caused by parasitic worms — is also more effective for lymphatic filariasis than the current gold standard, ivermectin.